Companies: ·total market cap:
$ USD
companiesbycap
Menu
Global rankingSuperinvestors
Countries
🇺🇸United States🇨🇦Canada🇩🇪Germany🇫🇷France🇬🇧United Kingdom🇨🇭Switzerland🇮🇳India🇯🇵Japan
Categories
💻Technology🏦Financials💊Healthcare🛍️Consumer Cyclical📡Communication🏭Industrials🛒Consumer DefensiveEnergy
ACAD
Acadia Pharmaceuticals Inc. ACAD
$20.91
▼ -1.40% 24H
0.6614.5028.3342.1656.002004-052009-112015-062020-122026-06

About

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological disorders and rare diseases. The company’s primary purpose is to address conditions with significant unmet medical needs, particularly in central nervous system indications. Acadia’s commercia

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees796
TickerACAD

Statistics

Market Cap$3.58B
Revenue (TTM)$1.07B
Net Income$391.0M
Net Margin36.5%
EPS$2.30
P/E9.68
P/S3.34
P/B2.93
EV/EBITDA30.61
ROE37.3%
Dividend Yield
Price$20.91

Data: Twelve Data · Revenue = mcap / P/S

Acadia Pharmaceuticals Inc. (ACAD) — Market Cap, Revenue, Net Income, P/E | companiesbycap